WAM
ASBP

Wolverine Asset Management’s Aspire Biopharma ASBP Stock Holding History

Wolverine Asset Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-419
Closed -$5.26M – 1944
2023
Q1 		$5.26M Buy
419
+3
+0.7% +$37.5K 0.06% 316
2022
Q4 		$5.14M Buy
416
+73
+21% +$894K 0.05% 333
2022
Q3 		$4.18M Sell
343
-304
-47% -$3.67M 0.05% 359
2022
Q2 		$7.75M Buy
+647
New +$7.75M 0.08% 254

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Wolverine Asset Management's ASBP Position: Q2 2023 in Review

Wolverine Asset Management sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 419 shares — an estimated $5.26M sold.

Wolverine Asset Management first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $7.75M in Q2 2022. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • Wolverine Asset Management reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • Wolverine Asset Management sold 419 Aspire Biopharma shares in Q2 2023, an estimated $5.26M.
  • Wolverine Asset Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • Wolverine Asset Management's Aspire Biopharma position peaked at $7.75M in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Wolverine Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.